natgillin/translations-raw huggingface dataset:
The compound for the use of claim 10, wherein the disease or disorder is selected from the group consisting of myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, artherosclerosis, traumatic central nervous system injury and ischemic heart disease. 
Spoj za uporabu u skladu s patentnim zahtjevom 10, naznačen time, da je bolest ili poremećaj odabran iz skupine koju čine infarkt miokarda, koronarna tromboza, vaskularna okluzija, postoperativna vaskularna reokluzija, ateroskleroza, traumatska ozljeda središnjeg živčanog sustava i ishemijska srčana bolest.
The compound for the use of claim 7, wherein the disease or disorder is an autoimmune disorder. 
Spoj za uporabu u skladu s patentnim zahtjevom 7, naznačen time, da je bolest ili poremećaj autoimuni poremećaj.
The compound for the use of claim 12, wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, Guillain-Barre syndrome, pancreatitis, lupus nephritis, lupus glomerulonephritis, psoriasis, Crohn's disease, vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, immunovasculitis, tissue graft rejection and hyperacute rejection of transplanted organs. 
Spoj za uporabu u skladu s patentnim zahtjevom 12, naznačen time, da je bolest ili poremećaj odabran iz skupine koju čine reumatoidni artritis, sistemski eritematozni lupus, Guillain-Barre sindrom, pankreatitis, lupus nefritis, lupus glomerulonefritis, psorijaza, Crohnova bolest, vaskulitis, sindrom iritabilnog crijeva, dermatomiozitis, multipla skleroza, bronhijalna astma, pemfigus, pemfigoid, skleroderma, mijastenija gravis, autoimuna hemolitička i trombocitopenična stanja, Goodpastureov sindrom, immunovasculitis, odbacivanje tkivnih transplantata i hiperakutno odbacivanje transplantiranih organa.
The compound for the use of claim 7, wherein the disease or disorder is a pathologic sequelae associated with the group consisting of insulin-dependent diabetes mellitus, lupus nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces. 
Spoj za uporabu u skladu s patentnim zahtjevom 7, naznačen time, da je bolest ili poremećaj patološka posljedica povezana sa skupinom koju čine dijabetes uvjetovan inzulinom, šećerna bolest, lupus nefropatija, Heymann nefritis, membranski nefritis, glomerulonefritis, reakcija osjetljivosti na kontakt te upala uslijed kontakta krvi s umjetnim površinama.
The compound for use of claim 15, for use in the treatment of cancer. 
Spoj za uporabu prema zahtjevu 15, naznačen time da je za uporabu za liječenje za raka.
The compound for use of claim 16, wherein the cancer is selected from the group consisting of: neuroblastoma, ovarian, colorectal cancer, melanoma, head and neck cancer, gastric carcinoma, lung carcinoma, breast cancer, glioblastoma, medulloblastoma, secretory breast cancer, salivary gland cancer, papillary thyroid carcinoma, adult myeloid leukemia, pancreatic cancer, and prostate cancer. 
Spoj za uporabu prema zahtjevu 16, naznačen time da je rak odabran iz skupine koju čine: neuroblastom, rak jajnika, rak debelog crijeva, melanom, rak glave i vrata, karcinom želuca, karcinom pluća, karcinom dojke, glioblastom, meduloblastom, sekretorni rak dojke, rak žlijezde slinovnice, papilarni karcinom štitnjače, mijeloična leukemija kod odraslih, rak gušterače i rak prostate.
The method according to Claim 2, wherein the undesired plants are undesired plants in 7- or later leaf stage. 
Postupak prema zahtjevu 2, naznačen time, da su neželjene biljke neželjene biljke u fazi 7 ili više listova.
The method according to claim 3, wherein the undesired plants are controlled or their growth is inhibited over at least 60 days after the application of the herbicidally active ingredients. 
Postupak prema zahtjevu 2, naznačen time, da su neželjene biljke kontrolirane ili je njihov rast inhibiran najmanje 60 dana nakon primjene herbicidno aktivnih sastojaka.
The method according to claim 3, wherein the undesired plants are noxious weeds in corn fields. 
Postupak prema zahtjevu 2, naznačen time, da su neželjene biljke štetni korov u poljima kukuruza.
Compound A having the structure: in the form of crystalline anhydrous polymorph A2 having the following crystal data, 
Spoj A koji ima sljedeću strukturu: [image] u obliku kristaliničnog anhidridnog polimorfnog oblika A2 sa sljedećim kristalnim podacima,
Orthorhombic crystal system; 
ortorompski kristalni sustav;
The Compound A of claim 1 that is at least 99% free of other solid forms of Compound A. 
Spoj A prema zahtjevu 1, naznačen time, da je najmanje 99% bez drugih krutih oblika spoja A.
A pharmaceutical composition comprising the Compound A of any of claims 1 to 6 and further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of carriers, excipients, diluents, additives, fillers, surfactants, binders, antimicrobial preservatives, viscosity enhancing agents, and buffers. 
Farmaceutski sastav, naznačen time, da sadrži spoj A iz bilo kojeg od zahtjeva 1 do 6 te da nadalje sadrži jedan ili više farmaceutski prihvatljivih sastojaka odabranih iz skupine koja se sastoji od nosača, ekscipijenata, razrjeđivača, aditiva, punila, tenzida, veziva, antimikrobnih konzervansa, sredstava za povećavanje viskoznosti i pufera.
The pharmaceutical composition of claim 7 that is formulated for ophthalmic administration. 
Farmaceutski sastav prema zahtjevu 7, naznačen time, da je formuliran za oftalmološku primjenu.
The pharmaceutical composition of claim 8 that is formulated as follows: Ingredient %, W/V 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da je formuliran kako slijedi:
A method of obtaining the Compound A according to any of claims 1 to 6, the method comprising the steps of suspending Compound A in an aqueous liquid vehicle and heating to about 40 degrees for at least 9 hours; or preferably at least 15 hours. 
Postupak dobivanja spoja A u skladu s bilo kojim od patentnih zahtjeva od 1 do 6, naznačen time, da postupak obuhvaća stupnjeve suspenzije spoja A u vodenom tekućem nosaču i zagrijavanje na oko 40 stupnjeva C u vremenu od najmanje 9 sati; ili poželjno od najmanje 15 sati.
A process as claimed in any one of the claims 1-6, wherein said at least one raw material includes at least one mineral acid. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što navedena najmanje jedna sirovina uključuje najmanje jednu mineralnu kiselinu.
A process as claimed in claim 7, wherein said at least one mineral acid is sulfuric acid. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je navedena najmanje jedna mineralna kiselina sumporna kiselina.
A process as claimed in any one of the claims 7-8, wherein said at least one mineral acid is hydrochloric acid. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 7-8, naznačen time što je navedena najmanje jedna mineralna kiselina klorovodična kiselina.
Use of chlorine dioxide for the reduction of the amount of chlorinated aromatic compounds occurring in a process for the production of chlorine dioxide. 
Upotreba klornog dioksida, naznačena time što je klorni dioksid namijenjen smanjivanju količine kloriranih aromatskih spojeva koji se pojavljuju u postupku proizvodnje klornog dioksida.
with the proviso that when Y is -OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of the groups from R1 to R8 is different from hydrogen. 
uz uvjet da kada Y je -OH, tada je A različita od alkil-skupine koja ima jedan atom ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do pet atoma ugljika, ili je alternativno, najmanje jedna od skupina od R1 do R8, različita od vodika.
Compound of formula (I) as defined in any one of the preceding claims 1 to 7 for use in the treatment of diseases based on the expression of CX3CR1 and p40 selected from the group comprising diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, myocardial infarction, angina, lupus erythematosus, psoriasis, and type II diabetes. 
Spoj formule (I) kao što je definiran u bilo kojem od prethodnih zahtjeva 1 do 7, naznačen time, da se upotrebljava u liječenju bolesti koje su bazirane na ekspresiji CX3CR1 i p40, a odabrane su iz skupine koju čine dijabetska nefropatija, Crohnova bolest, ulcerativni kolitis, koronarni poremećaji, restenoza, infarkt miokarda, angina, lupus eritematoza, psorijaza i dijabetes tipa II.
Compound for use according to Claim 1, characterized in that X1 is chosen from the group comprising a group CH2, a group CH2CH2 or a group C(CH3)2, and R9 and R10, which may be identical or different each other, are hydrogen or a CH3 group. 
Spoj prema zahtjevu 1, naznačen time, da X1 je izabrana iz skupine koja obuhvaća CH2-skupinu, CH2CH2-skupinu ili C(CH3)2-skupinu, te su R9 i R10, koje mogu biti međusobno identične ili različite, vodik ili CH3-skupina.
Compound for use according to Claim 1, characterized in that residue A is chosen from the group comprising a group CH2, a group CH2CH2, a group C(CH3)2, a group CH2CH2OCH2, a group CH2CH2OC(CH3)2 and a group CH2CH2CH2OC(CH3)2. 
Spoj prema zahtjevu 1, naznačen time, da je ostatak A izabran iz skupine koja obuhvaća CH2-skupinu, CH2CH2-skupinu, C(CH3)2-skupinu, CH2CH2OCH2-skupinu, CH2CH2OC(CH3)2-skupinu, te CH2CH2CH2OC(CH3)2-skupinu.
Compound for use according to Claim 1, characterized in that R3, R4 and R8, which may be identical or different each other, are chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a Br, Cl or F atom, an OH group, a nitro group, a trifluoromethyl group or a group N(R')(R") or -N(R')COR", -CN, -CONR'R", -SO2NR'R", -SO2R', with R' and R", which may be identical or different each other, represented by a hydrogen atom and an alkyl group having from 1 to 3 carbon atoms. 
Spoj prema zahtjevu 1, naznačen time, da su R3, R4 i R8, koje mogu biti međusobno identične ili različite, izabrane iz skupine koju čine atom vodika, alkil-skupina koja ima od jednoga do tri atoma ugljika, alkoksi-skupina koja ima od jednoga do dva atoma ugljika, atom Br, atom Cl ili atom F, OH-skupina, nitro-skupina, trifluorometil-skupina, ili -N(R')(R'')-skupina ili N(R')COR'', -CN, -CONR'R'', -SO2NR'R'', -SO2R', s R' i R'', koje mogu biti međusobno identične ili različite, a predstavljene su atomom vodika i alkil-skupinom koja ima od jednoga do tri atoma ugljika.
Compound for use according to Claim 1, characterized in that R6 and R7, which may be identical or different each other, are chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, or together form a group C=O, or one from among R6 and R7, together with R5, forms a ring having 5 or 6 carbon atoms. 
Spoj prema zahtjevu 1, naznačen time, da su R6 i R7, koje mogu biti međusobno identične ili različite, izabrane iz skupine koju čine atom vodika, alkil-skupina koja ima od jednoga do tri atoma ugljika, ili zajedno tvore skupinu C=O, ili jedan od R6 i R7, zajedno s R5, tvori prsten koji ima pet ili šest atoma ugljika.
Pharmaceutical composition for use according to Claim 8, characterized in that the said pharmaceutically acceptable salt is an addition salt with physiologically acceptable organic or mineral acids or bases. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da je navedena farmaceutski prihvatljiva sol takva, da je to adicijska sol s fiziološki prikladnim organskim ili mineralnim kiselinama ili lužinama.
Pharmaceutical composition for use according to Claim 9, characterized in that the said physiologically acceptable bases are chosen from the group comprising ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine. 
Farmaceutski sastav prema zahtjevu 9, naznačen time, da su navedene fiziološki prikladne lužine izabrane iz skupine koju čine amonijev hidroksid, kalcijev hidroksid, magnezijev karbonat, natrijev vodikov karbonat, kalijev vodikov karbonat, arginin, betain, kafein, kolin, N,N-dibenziletilendiamin, dietilamin, 2-dietilaminoetanol, 2-dimetilaminoetanol, etanolamin, etilendiamin, N-etilmorfolin, N-etilpiperidin, N-metilglukamin, glukamin, glukozamin, histidin, N-(2-hidroksietil)piperidin, N-(2-hidroksietil)pirolidin, izopropilamin, lizin, metilglukamin, morfolin, piperazin, piperidin, teobromin, trietilamin, trimetilamin, tripropilamin i trometamin.
Pharmaceutical composition for use according to Claim 8, characterized in that the said pharmaceutically acceptable ester is formed with physiologically acceptable organic acids or alcohols. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da je navedeni farmaceutski prihvatljiv ester stvoren s fiziološki prikladnim organskim kiselinama ili alkoholima.
The compound according to Claim 7 which is a hydrate in a crystalline form characterized by a X-ray powder diffraction pattern having characteristic peaks, in 2θ ± 0.2, occurring at 22.27 and one or more of 13.46, 16.54, 16.66, 18.10 and 23.13. 
Spoj u skladu s patentnim zahtjevom 7, koji je hidrat u kristalnom obliku naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu s karakterističnim signalima, u 2θ ± 0,2, na 22,27 i jednim ili više od 13,46, 16,54, 16,66, 18,10 i 23,13.
An antibody that specifically binds human CSF-1R (SEQ ID NO. 
Protutijelo koje se specifično veže na ljudski CSF-1R (SEQ ID NO.
A pharmaceutical composition comprising the antibody of any one of Claims 1-3 together with a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
A pharmaceutical composition of Claim 4 further comprising an additional pharmaceutical agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što dodatno sadrži dodatno farmaceutsko sredstvo.
The antibody for use according to Claim 7, wherein the cancer is leukemia, breast cancer, endometrial cancer, prostate cancer, ovarian cancer, colorectal cancer, hepatocellular cancer, renal cancer, multiple myeloma, or Hodgkin's lymphoma. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 7, naznačeno time što je rak leukemija, rak dojke, rak endometrija, rak prostate, rak jajnika, kolorektalni rak, hepatocelularni rak, rak bubrega, multipli mielom ili Hodgkinov limfom.
The antibody for use according to Claims 6-10, wherein the antibody is administered before, during, substantially simultaneously with, or after commencing therapy with another anti-cancer treatment. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevima 6-10, naznačeno time što se protutijelo primijenjuje prije, za vrijeme, uglavnom istodobno s ili nakon početka terapije drugim antikanceroznim liječenjem.
The antibody for use according to Claim 11, wherein said anti-cancer treatment is selected from the group consisting of an anti-angiogenesis agent, a chemotherapeutic agent, and an anti-neoplastic agent. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što se navedeno antikancerozno liječenje bira iz skupine koju čine antiangiogenetsko sredstvo, kemoterapijsko sredstvo i antineoplastično sredstvo.
The antibody for use according to Claim 12, wherein said anti-neoplastic agent is selected from the group consisting of docetaxel, paclitaxel, Herceptin® and doxorubicin. 
Protutijelo, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačeno time što se navedeno antineoplastično sredstvo bira iz skupine koju čine docetaksel, paklitaksel, Herceptin® i doksorubicin.
A method for determining whether a subject having a cancer is a candidate for an anti-CSF-1R antibody-based cancer treatment regimen, wherein said antibody is the antibody of any one of Claims 1-3, comprising: 
Postupak određivanja je li subjekt koji ima rak kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R, gdje je navedeno protutijelo protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što se sastoji u:
ex vivo or in vitro determining the level of CSF-1, or IL-34, or both, in a sample of the subject, wherein the sample is selected from the group consisting of blood, serum, plasma, tumor cells and circulating tumor cells, wherein an increase in the level of CSF-1, or IL-34, or both, as compared with the level of CSF-1, or IL-34, or both, in an individual not suffering from cancer, is indicative that the subject is a candidate for the anti-CSF-1R antibody-based cancer treatment regimen. 
određivanju razine CSF-1 ili IL-34, ili oba, ex vivo ili in vitro u uzorku iz subjekta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, gdje porast razine CSF-1, ili IL-34, ili oba, u usporedbi s razinom CSF-1, ili IL-34, ili oba, kod pojedinca koji ne boluje od raka, ukazuje da je subjekt kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R.
conversion in acid environment of Amidine of formula (III): to compound of formula (II), wherein the conversion is carried out in ethanol, 
pretvorba u kiselom mediju amidina formule (III): [image] u spoj formule (II), gdje se pretvorba provodi u etanolu,
obtaining suspension of compound (II) in ethanol, without the addition of any other solvent, 
dobivanje suspenzije spoja (II) u etanolu, bez dodavanja ikakvog drugog otapala,
Process according to claim 1, wherein the conversion of the step a) is carried out dosing a solution of gaseous hydrochloric acid on denatured ethyl alcohol to a mixture of Amidine of formula (III) and ethanol. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se pretvorba iz koraka a) provodi doziranjem otopine plinovite klorovodične kiseline u denaturiranom etil-alkoholu u smjesu amidina formule (III) s etanolom.
Process according to anyone of the claims from 1 to 2, wherein in the step a) or in both the steps step a) and step b), ethanol contains an amount of water lower than 0.10 volumes compared to the compound of formula (III). 
Postupak u skladu s bilo kojim od patentnih zahtjeva od 1 do 2, naznačen time što u koraku a) ili i u koraku a) i u koraku b) etanol sadrži količinu vode koja je manja od 0,10 volumena u usporedbi sa spojem formule (III).
Process according to anyone of the claims from 1 to 4, wherein the both steps a) and b) are carried out with an amount of volumes of ethanol comprised between about 1 and about 6 compared to the compound of formula (III). 
Postupak u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, naznačen time što se oba koraka a) i b) provode uz volumnu količinu etanola koja se kreće između otprilike 1 i otprilike 6 u usporedbi sa spojem formule (III).
Process according to anyone of the claims from 1 to 8, wherein the conversion of step a) is carried out by means of gaseous hydrochloric acid. 
Postupak u skladu s bilo kojim od patentnih zahtjeva od 1 do 8, naznačen time što se pretvorba iz koraka a) provodi uz pomoć plinovite klorovodične kiseline.
conversion of Triazole of the step A) to obtain Sitagliptin. 
pretvorba triazola iz koraka A) kako bi se dobio sitagliptin.
the enzymatic conversion of Ketoamide of formula (IV), obtained by previous step C1), to Sitagliptin of formula (I): 
enzimska pretvorba ketoamida formule (IV), dobivenog u prethodnom koraku C1), u sitagliptin formule (I): [image] .
Monoclinic crystal system; 
ortorompski kristalni sustav;
A pharmaceutical composition comprising Compound A as defined in any of claims 1 to 6 and further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of carriers, excipients, diluents, additives, fillers, surfactants, binders, antimicrobial preservatives, viscosity enhancing agents, and buffers. 
Farmaceutski sastav, naznačen time, da sadrži spoj A iz bilo kojeg od zahtjeva 1 do 6 te da nadalje sadrži jedan ili više farmaceutski prihvatljivih sastojaka odabranih iz skupine koja se sastoji od nosača, ekscipijenata, razrjeđivača, aditiva, punila, tenzida, veziva, antimikrobnih konzervansa, sredstava za povećavanje viskoznosti i pufera.
A compound for use according to claim 13, for use in the treatment of cancer. 
Spoj za uporabu prema zahtjevu 15, naznačen time da je za uporabu za liječenje za raka.
A compound for use according to any one of claims 13-14, wherein the cancer is selected from the group consisting of neuroblastoma, ovarian cancer, colorectal cancer, melanoma, head and neck cancer, gastric cancer, gastric carcinoma, lung carcinoma, breast cancer, glioblastoma, medulloblastoma, secretory breast cancer, salivary gland cancer, papillary thyroid carcinoma, adult myeloid leukemia, pancreatic cancer, and prostate cancer. 
Spoj za uporabu prema zahtjevu 16, naznačen time da je rak odabran iz skupine koju čine: neuroblastom, rak jajnika, rak debelog crijeva, melanom, rak glave i vrata, karcinom želuca, karcinom pluća, karcinom dojke, glioblastom, meduloblastom, sekretorni rak dojke, rak žlijezde slinovnice, papilarni karcinom štitnjače, mijeloična leukemija kod odraslih, rak gušterače i rak prostate.
The coating particles according to Claim 5, wherein a volume average primary particle size of the core particles 5 µm to 1000 µm. 
Čvrsta formulacija prema zahtjevu 1, naznačena time, da prosječni volumen primarne veličine čestice od jezgrenih čestica, iznosi od 5 μm do 1000 μm.
The coating particles according to Claim 8, wherein a volume average primary particle size of the drug particles is smaller than a volume average primary particle size of the core particles. 
Čvrsta formulacija prema zahtjevu 6, naznačena time, da je prosječni volumen primarne veličine čestice od čestica ljekovite tvari, manji od prosječnog volumena primarne veličine čestice od jezgrenih čestica.
A compound represented by general formula (I) or a pharmacologically acceptable salt thereof: wherein each substituent is as defined below: 
Spoj koji je predstavljen općom formulom (I) ili njegova farmakološki prihvatljiva sol, ili hidrat spoja ili njegova farmakološki prihvatljiva sol: [image] gdje je svaki supstituent kao što je definirano ispod:
The pharmacologically acceptable salt according to claim 15 or 16, which is a hydrate thereof. 
Farmakološki prihvatljiva sol u skladu sa patentnim zahtjevom 15 ili 16, koja je njen hidrat.
A compound according to claim 1, having the structure wherein m is not 0. 
Tvar u skladu s patentnim zahtjevom 1, koja ima strukturu [image] gdje m nije 0.
A compound according to claim 12, wherein the radioisotope is selected from the group consisting of 18F, 123I, 124I, 125I, 126I, 131I, 75Br, 76Br, 77Br, 80Br, 80mBr, 82Br, 83Br and 211At. 
Tvar u skladu s patentnim zahtjevom 12, gdje je radioizotop odabran iz grupe koja se sastoji od 18F, 123I, 124I, 125I, 126I, 131I, 75Br, 76Br, 77Br, 80Br, 80mBr, 82Br, 83Br i 211At.
A compound according to claim 1 selected from the group consisting of or a pharmaceutically acceptable salt thereof. 
Tvar u skladu s patentnim zahtjevom 1 odabrana iz grupe koja se sastoji od [image] i ili njihove farmaceutski prihvatljive soli.